Based on new clinical evidence, the National Comprehensive Cancer Network (NCCN) annually updates and releases the "NCCN Guidelines for the Clinical Diagnosis and Treatment of Non-Small Cell Lung Cancer" which has become the reference for clinical diagnosis and treatment approved and complied by clinicians worldwide. On November 25, 2020, the latest 2021 V1 version of "NCCN Clinical Diagnosis and Treatment Guidelines for Non-Small Cell Lung Cancer" (hereinafter referred to as "Guidelines") was released. Compared with the 8th edition of the "Guidelines" in 2020, many updates focused on the progress of targeted and immunotherapy. This article will provide the interpretations of the updated therapy content of this edition of the guidelines.
Segmentectomy is the removal of certain segments of the lung with lesions and retaining the normal lung tissue of the lobe. Lung segmentectomy is considered difficult due to the lack of clear anatomical boundaries between lung segments. Segmentectomy has a variety of indications, such as lung cancer, metastatic lung tumors, and many non-malignant diseases. In the treatment of early stage lung cancer, segmentectomy was initially considered only as a treatment option for patients not suitable for conventional lobectomy. As more evidence emerged, the indications for segmentectomy have continued to change over time, and segmentectomy has been widely performed in patients with early stage lung cancer. Theoretically, segmentectomy leads to better preservation of lung function than lobectomy, but the risk of incomplete tumor resection is higher, so the indication of segmentectomy has become a focus of debate. This article will introduce the surgical techniques of segmentectomy and summarize the published and unpublished clinical studies on segmentectomy for the treatment of early stage lung cancer.
The National Comprehensive Cancer Network (NCCN) released the latest version 1, 2022 of "NCCN guidelines for the clinical diagnosis and treatment of small cell lung cancer" (hereinafter referred to as "guideline"). Based on high-quality evidence-based medicine, this guideline provides references of clinical diagnosis and treatment for clinicians around the world. Compared with the version 3, 2021 of the "guideline", updates and revisions mainly focused on the progress of radiotherapy and systemic treatment. This article will interpret the updated therapy content in this new version of the "guideline".
With the development of precision diagnosis and treatment of lung cancer, anatomical segmentectomy has become an important surgical procedure for the treatment of early-stage lung cancer. After the widespread popularization of video-assisted thoracoscopic surgery (VATS), the treatment of lung cancer has entered the era of minimally invasive surgery. Since it was first reported in 2012, uniportal video-assisted anatomical segmentectomy has gained increasing clinical application. Uniportal VATS is less invasive than thoracotomy and traditional VATS. At present, the main research hotspots around uniportal video-assisted anatomical segmentectomy include specific indications, short-term and long-term efficacy, and learning curve. This article will introduce the characteristics, indications and surgical techniques of this procedure, then summarize and discuss the latest research progress of uniportal video-assisted anatomical segmentectomy based on the latest evidence-based evidence.
ObjectiveTo systematically review the effectiveness of different pharmacologic agents administered via ultrasound-guided intra-articular injection for pain relief and functional improvement in early-to-mid stage knee osteoarthritis. MethodsThe PubMed, Web of Science, Cochrane Library, Embase, CNKI, VIP, WanFang Data, SinoMed, ClinicalTrials.gov, and the WHO international clinical trials registry platform were electronically searched to collect randomized controlled trials (RCTs) related to the objectives from inception to May 8, 2025. Two reviewers independently screened literature, extracted data and assessed the risk of bias of the included studies. The network meta-analysis was then performed by using R 4.4.3 software. ResultsA total of 23 RCTs involving 1 587 participants and nine intervention strategies were included. The results revealed: (1) For pain relief, platelet-rich plasma combined with ultrasound guidance ranked highest; (2) In terms of functional improvement, platelet-rich plasma demonstrated consistent advantages across multiple dimensions of joint function, stiffness, and total score; (3) Hypertonic dextrose and autologous adipose tissue injections showed potential benefits in specific outcome dimensions; (4) Interventions such as traditional blind injections, corticosteroids, and ozone ranked moderately; (5) Safety: Based on limited reports, current evidence indicates that adverse events were predominantly mild and transient local reactions, with no serious events directly attributable to the interventions. ConclusionCurrent evidence shows that platelet-rich plasma under ultrasound guidance demonstrated a consistent advantage across multiple outcome measures, characterized by favorable safety, targeting precision, and clinical applicability.
